Brief: Sprint Bioscience License Partner Sells Petra01-Project To Hibercell
March 8 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* LICENSE PARTNER HAS SOLD PETRA01-PROJECT TO HIBERCELL
* LICENCE AGREEMENT WITH CO STAYS UNCHNAGED AFTER
TRANSACTION
* PARTNER RAVENNA PHARMACEUTICALS SELLS PETRA01-PROJECT TO
HIBERCELL
Source text for Eikon: ID:nWkr37DmT
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln
Brief: Sprint Bioscience Completes Strategic Evaluation Of STK25 Program
Brief: Sprint Bioscience Appoints Jenni Björnulfson As CFO
Brief: Sprint Bioscience Reports Positive Proof-Of-Concept Results From Program In CKD
Brief: Sprint Bioscience Reports Positive Results From The Vrk1 Program